Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression

BACKGROUND: Glioblastoma (GBM) patients are treated with radiation therapy, chemotherapy, and corticosteroids, which can cause myelosuppression. To understand the relative prognostic utility of blood-based biomarkers in GBM and its implications for clinical trial design, we examined the incidence, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Davy, Hammoudeh, Lubna, Youssef, Gilbert, Chen, Yu-Hui, Shin, Kee-Young, Lim-Fat, Mary Jane, McFaline-Figueroa, Jose Ricardo, Chukwueke, Ugonma N, Tanguturi, Shyam, Reardon, David A, Lee, Eudocia Q, Nayak, Lakshmi, Bi, Wenya Linda, Arnaout, Omar, Ligon, Keith L, Wen, Patrick Y, Rahman, Rifaquat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406420/
https://www.ncbi.nlm.nih.gov/pubmed/37554224
http://dx.doi.org/10.1093/noajnl/vdad083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406420/
https://www.ncbi.nlm.nih.gov/pubmed/37554224
http://dx.doi.org/10.1093/noajnl/vdad083

Ejemplares similares